drugset / Trial / NCT07270042

Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection

NCT07270042

Not yet recruiting 20 enrolled Latakia University
RandomizedSequentialDouble-blindTreatment

Summary

This clinical trial seeks to investigate a promising new approach to enhance the effectiveness and duration of Botulinum Toxin A (BTX-A) for the treatment of hyperactive masseter muscles. By investigating the role of oral zinc supplementation, this study could provide a cost-effective, sustainable solution for patients suffering from both aesthetic concerns and functional limitations associated with MMH and bruxism. The findings of this study will expand the clinical applications of BTX-A, offering longer-lasting relief and reducing the need for frequent injections, which could revolutionize the management of MMH in clinical practice.

Timeline

Start
2025-12-01
Primary completion
2026-09-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 25 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 30 iu Intramuscular
Subject Zinc gluconate Small molecule 50 mg Oral